Evidence map›Paper›PMID 39957840›Full record

ArticleAdvanced nanobiomed research2024

Engineering and Monitoring the Sustained Release of Extracellular Vesicles from Hydrogels for

Selen Uman, Noah Weingarten, Mark Helmers, Amit Iyengar, Karen L Xu, Kendra Worthington, Danika Meldrum, Jessica Dominic, Sara Guevara-Plunkett, Alexis Schiazza and 2 more

Abstract read
In one paragraph

Article in Advanced nanobiomed research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Selen UmanDepartment of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.
Noah WeingartenDivision of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Mark HelmersDivision of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Amit IyengarDivision of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Karen L XuDepartment of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kendra WorthingtonBioFrontiers Institute and Department of Chemical and Biological Engineering, University of Colorado, Boulder, CO, 80303, USA.
Danika MeldrumDivision of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Jessica DominicDivision of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Sara Guevara-PlunkettDivision of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Alexis SchiazzaDivision of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Pavan AtluriDivision of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Jason A BurdickBioFrontiers Institute and Department of Chemical and Biological Engineering, University of Colorado, Boulder, CO, 80303, USA.

Funding

Engineered Granular Hydrogels for Endogenous Tissue RepairR01HL160616 · NHLBI · UNIVERSITY OF COLORADO · PI BURDICK, JASON A · 2022 to 2025
$2.5M
A Novel Shear Thinning Hydrogel System for Advanced Cellular Therapy in Ischemic Heart DiseaseR01HL135090 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ATLURI, PAVAN · 2017 to 2021
$2.4M
Injectable Fibrous Scaffolds for Meniscal RepairF30AG074508 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XU, KAREN · 2021 to 2023
$138k
NHLBI NIH HHS R01 HL135090NHLBI NIH HHS R01 HL160616NIA NIH HHS F30 AG074508
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are gaining interest in regenerative medicine and biomaterials have been shown to extend EV bioavailability following delivery. Here, we report the labeling of both hydrogels and EVs to better understand hydrogel design for sustained EV release into tissues. Shear-thinning hydrogels were engineered using guest-host (i.e., adamantane-cyclodextrin) modifications to hyaluronic acid (GH), as well as GH hydrogels with the addition of gelatin crosslinked via transglutaminase (GH+Gel) to temporally control hydrogel properties. When labeled with a near-IR dye and injected into rat myocardial tissue, the GH+Gel hydrogel was retained (>14 days) longer than the GH hydrogel alone (~7 days), likely due to the added gelatin network. To overcome challenges associated with common EV labeling methods, we utilized a highly versatile metabolic labeling methodology via the incorporation of Ac4ManNAz during EV synthesis to introduce azide groups that could then be reacted with DBCO-dyes. When injected in saline, EVs were cleared within 24 hours in hearts; however, hydrogels enhanced EV retention, with levels based on hydrogel degradation behavior, namely >14 days for GH+Gel hydrogel and ~7 days for GH hydrogel alone. These findings support the use of hydrogels in EV therapies to help retain their presence at desired tissue sites.

Indexed as

biomaterialsdrug deliveryExtracellular vesicleshydrogelsmetabolic labeling

Identifiers

PMID39957840
PMCPMC11824923

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.